Yang Huang
JPMorgan Chase & Co, Research Division
Good morning, everyone. Welcome to this session. I’m Yang Huang, China health care analyst of JPMorgan based in Hong Kong.
Welcome to this session to be presented by WuXi Biologics. And the presenter will be WuXi Biologics’ CEO, Dr. Chris Chen. Dr. Chen, we can get started.
Chris Chen
CEO & Executive Director
Good morning. It’s my time to report to you guys every year about the exciting progress of WuXi Biologics. So this year, we chose the title of A Scaled CRDMO Platform Delivering Sustainable High Growth. The scale at WuXi Biologics is incredible, and our business model, CRDMO, is very unique. And we want to make sure that we can deliver sustainable high growth.
I’m going to start with briefly talking about our business model, mostly give you guys a business update and strategic footprint expansion. I cannot come to this conference without showcasing our technology leadership and our ESG progress. And then I’ll give you a summary and outlook.
Our business model is incredibly — again, we said we are a scaled, integrated CRDMO model, basically a one-stop shop and with a huge scale. So our vision is every biologic can be made. We have delivered on that vision for the past 15 years. Every project that came to WuXi, we delivered. That’s not an easy statement. Every biologic project that came to WuXi, we delivered. And that’s why our mission — our vision is every biologic can be made.
We said our mission is accelerating the discovery, development and
